GENE ONLINE|News &
Opinion
Blog

Sarepta Therapeutics
Trials & Approvals Duchenne Muscular Dystrophy-dmd
Sarepta Submits BLA for First-Ever Duchenne Muscular Dystrophy Gene Therapy
2022-10-03
Special JPM
JPM22 Highlights: Cell and Gene Therapies Rise Up
2022-01-11
Trials & Approvals Gene Therapy
Sarepta to Begin Phase 3 Rivalry with Pfizer after its DMD Gene Therapy Registers Encouraging Data
2021-05-21
Trials & Approvals Gene Therapy
Sarepta’s Stocks Drop 50% Following Middling Trial Data for Gene Therapy
2021-01-11
R&D
Sarepta and Codiak Biosciences Join Hands to Tackle Rare Diseases Using Exosome-Based Therapeutics
2020-06-26
Technology CRISPR
Scientists Use CRISPR To Fight Duchenne Muscular Dystrophy
2020-01-29
LATEST
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
SURMOUNT-5 Trial: Zepbound Shows Greater Weight Loss Than Wegovy
2025-05-14
ASCGT Meeting Navigates Biotech Downturn After Multi-Year Slump
2025-05-14
READ MORE
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-26
2025 Antibody Therapeutic & Frontiers in Biomedical Sciences Conference
Taipei, Taiwan
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2025 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top